Lanreotide Viatris (Lanreotide)

Lanreotide is a synthetic analogue of somatostatin. It binds to somatostatin receptors (mainly subtypes 2 and 5) on endocrine cells, inhibiting the release of growth hormone, insulin, glucagon and various gastrointestinal peptides. This receptor‑mediated blockade reduces hormone‑driven disease activity.

The dosage and administration schedule for Lanreotide Viatris are determined by the prescribing clinician based on the patient’s condition, response and tolerability. The prescriber will select the appropriate injection frequency and amount according to current clinical guidelines.

Safety data for lanreotide during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the Lanreotide Viatris product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain where applicable) and required import documentation.

The primary alternative to lanreotide is octreotide, another somatostatin analogue. Both agents suppress growth hormone and tumor‑related hormone secretion, but lanreotide is formulated for less frequent dosing (often every 4 weeks) whereas octreotide typically requires more frequent injections. Choice depends on patient preference, tolerability and physician assessment.

Lanreotide Viatris should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before administration, gently invert the vial to ensure a uniform suspension; do not shake vigorously.

Lanreotide Viatris is administered as a subcutaneous injection. The healthcare professional prepares the injectable suspension according to the product’s instructions and injects it into the subcutaneous tissue, usually in the abdomen or thigh. Injection intervals are set by the prescriber, commonly every 4 weeks for chronic therapy.

Serious adverse events include gallstone formation, acute pancreatitis and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for abdominal pain, persistent nausea, vomiting, jaundice, or signs of an allergic reaction, and they should seek immediate medical attention if these occur.

Lanreotide Viatris is contraindicated in individuals with known hypersensitivity to lanreotide or any component of the formulation. Caution is advised for patients with uncontrolled diabetes, severe gallbladder disease, or a history of pancreatitis. Pregnant or nursing women should only use it if clearly indicated by a physician.